RBC Reiterates 'Outperform' Rating on Agilent Technologies with $153 Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Rating Reaffirmation and Target Price: RBC Capital Markets reiterated its 'outperform' rating on Agilent Technologies and set a price target of $153, reflecting confidence in the company's future performance.
- Organic Growth Expectations: RBC anticipates Agilent's organic sales growth rate to be 5.5% from 2026 to 2028, surpassing peers' 4.5%, indicating a competitive edge in the industry.
- Valuation Analysis: The target price is based on approximately 18 times forward EBITDA, slightly above the peer median of 16.5 times, suggesting market recognition of Agilent's future profitability.
- Risk Advisory: RBC cautioned that Agilent is more sensitive to macroeconomic cycles than its peers, particularly noting that 18% of its sales come from China, highlighting potential risks in industrial markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy A?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on A
Wall Street analysts forecast A stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 115.080
Low
160.00
Averages
171.67
High
180.00
Current: 115.080
Low
160.00
Averages
171.67
High
180.00
About A
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agilent Technologies Set to Report Earnings
- Earnings Preview: Agilent Technologies is set to report earnings this Wednesday after the bell, with market expectations for an 8% year-on-year revenue growth, an improvement from the 6% increase recorded in the same quarter last year, indicating the company's stability and growth potential in the market.
- Revenue Performance: Last quarter, Agilent reported revenues of $1.80 billion, up 7% year-on-year, and while the revenue guidance exceeded analysts' expectations, the actual revenue was in line with estimates, reflecting uncertainty in the company's revenue forecasting.
- Market Sentiment: Investor sentiment in the research tools and consumables sector has been positive, with average share prices rising 2.7% over the past month, whereas Agilent's stock has declined by 1.2%, indicating a cautious outlook on its future performance.
- Analyst Expectations: Most analysts have reaffirmed their estimates for Agilent over the past 30 days, with an average price target of $161.13 compared to the current share price of $114.96, suggesting a generally optimistic view on the company's future growth.
See More
RBC Reiterates 'Outperform' Rating on Agilent Technologies with $153 Target
- Rating Reaffirmation and Target Price: RBC Capital Markets reiterated its 'outperform' rating on Agilent Technologies and set a price target of $153, reflecting confidence in the company's future performance.
- Organic Growth Expectations: RBC anticipates Agilent's organic sales growth rate to be 5.5% from 2026 to 2028, surpassing peers' 4.5%, indicating a competitive edge in the industry.
- Valuation Analysis: The target price is based on approximately 18 times forward EBITDA, slightly above the peer median of 16.5 times, suggesting market recognition of Agilent's future profitability.
- Risk Advisory: RBC cautioned that Agilent is more sensitive to macroeconomic cycles than its peers, particularly noting that 18% of its sales come from China, highlighting potential risks in industrial markets.
See More
Wall Street's Latest Rating Changes Overview
- Openlane Upgrade: JPMorgan upgraded Openlane from neutral to overweight and raised its December 2026 price target to $38, indicating that the online used car marketplace is experiencing robust growth and has potential for sustainable expansion over the coming years.
- Dollar General Downgrade: Deutsche Bank downgraded Dollar General from buy to hold, citing challenges in its customer base and the widening gap in the K-shaped economy, which may limit same-store sales upside, reflecting a cautious outlook on the company.
- Ecolab Upgrade: UBS upgraded Ecolab from neutral to buy and raised its price target to $325, demonstrating strong demand and positive performance expectations for the chemicals company amid a favorable market environment.
- FedEx Upgrade: JPMorgan upgraded FedEx from neutral to overweight, expressing optimism ahead of its upcoming earnings report, particularly regarding the separation of its freight business, which is seen as an attractive risk-reward opportunity.
See More
Agilent Technologies Set to Release FY Earnings Results
- Earnings Announcement: Agilent Technologies is set to announce its FY earnings results on May 27th after market close, with consensus EPS estimate at $5.97 and revenue estimate at $7.39 billion, indicating strong financial expectations from the market.
- Performance Beat Record: Over the past two years, Agilent has beaten EPS estimates 88% of the time and revenue estimates 75% of the time, reflecting its sustained competitiveness and profitability in the market.
- Revision Trends: In the last three months, EPS estimates have seen 14 upward revisions and 2 downward revisions, while revenue estimates have experienced 15 upward revisions with no downward adjustments, showcasing analysts' optimistic outlook on the company's future performance.
- Strategic Acquisition: Agilent announced the acquisition of Biocare Medical for $950 million, aimed at expanding its pathology portfolio, which not only strengthens the company's market position but also has the potential to drive future revenue growth.
See More
Stock Market Shows Strength Ahead of Holiday Weekend
- Market Recovery: The S&P 500 index reached a record high above 7,500 in May after recovering from March lows, indicating strong market recovery, although it remains just below that record, reflecting optimistic investor sentiment.
- Declining Cash Holdings: A Bank of America Securities survey shows professional investors' cash levels dropped from 4.3% to 3.9%, nearing the 4.0% sell signal, indicating that investors are chasing the market rally but may soon face capital shortages.
- Increased Inflation Pressure: The upcoming personal consumption expenditures price index is expected to show core PCE rising to 3.4% year-over-year in April, up from 3.2% in March, potentially increasing pressure on the Federal Reserve to raise interest rates, which could affect market sentiment.
- Economic Data Impact: Next week will see several economic data releases and earnings reports from key tech companies that could significantly impact the markets, particularly consumer commentary from Costco and Dollar Tree, which may trigger market volatility.
See More
Agilent Technologies Declares Quarterly Dividend of $0.255
- Quarterly Dividend Announcement: Agilent Technologies has declared a quarterly dividend of $0.255 per share, consistent with previous announcements, reflecting the company's stable cash flow and profitability, which is likely to attract more income-focused investors.
- Dividend Yield: The forward yield of this dividend stands at 0.9%, which, while relatively low, still offers a return in the current market environment, potentially increasing investor interest in the company's stock.
- Consistent Dividend Payments: Agilent has now announced a dividend of $0.255 for three consecutive quarters, indicating confidence in future cash flows and potentially enhancing market perceptions of its financial health.
- Shareholder Record Date: The dividend will be payable on July 22 for shareholders of record on June 30, with the ex-dividend date also set for June 30, ensuring timely returns for shareholders and further solidifying trust between the company and its investors.
See More
Agilent Technologies Set to Report Earnings
- Earnings Preview: Agilent Technologies is set to report earnings this Wednesday after the bell, with market expectations for an 8% year-on-year revenue growth, an improvement from the 6% increase recorded in the same quarter last year, indicating the company's stability and growth potential in the market.
- Revenue Performance: Last quarter, Agilent reported revenues of $1.80 billion, up 7% year-on-year, and while the revenue guidance exceeded analysts' expectations, the actual revenue was in line with estimates, reflecting uncertainty in the company's revenue forecasting.
- Market Sentiment: Investor sentiment in the research tools and consumables sector has been positive, with average share prices rising 2.7% over the past month, whereas Agilent's stock has declined by 1.2%, indicating a cautious outlook on its future performance.
- Analyst Expectations: Most analysts have reaffirmed their estimates for Agilent over the past 30 days, with an average price target of $161.13 compared to the current share price of $114.96, suggesting a generally optimistic view on the company's future growth.
See More
RBC Reiterates 'Outperform' Rating on Agilent Technologies with $153 Target
- Rating Reaffirmation and Target Price: RBC Capital Markets reiterated its 'outperform' rating on Agilent Technologies and set a price target of $153, reflecting confidence in the company's future performance.
- Organic Growth Expectations: RBC anticipates Agilent's organic sales growth rate to be 5.5% from 2026 to 2028, surpassing peers' 4.5%, indicating a competitive edge in the industry.
- Valuation Analysis: The target price is based on approximately 18 times forward EBITDA, slightly above the peer median of 16.5 times, suggesting market recognition of Agilent's future profitability.
- Risk Advisory: RBC cautioned that Agilent is more sensitive to macroeconomic cycles than its peers, particularly noting that 18% of its sales come from China, highlighting potential risks in industrial markets.
See More
Wall Street's Latest Rating Changes Overview
- Openlane Upgrade: JPMorgan upgraded Openlane from neutral to overweight and raised its December 2026 price target to $38, indicating that the online used car marketplace is experiencing robust growth and has potential for sustainable expansion over the coming years.
- Dollar General Downgrade: Deutsche Bank downgraded Dollar General from buy to hold, citing challenges in its customer base and the widening gap in the K-shaped economy, which may limit same-store sales upside, reflecting a cautious outlook on the company.
- Ecolab Upgrade: UBS upgraded Ecolab from neutral to buy and raised its price target to $325, demonstrating strong demand and positive performance expectations for the chemicals company amid a favorable market environment.
- FedEx Upgrade: JPMorgan upgraded FedEx from neutral to overweight, expressing optimism ahead of its upcoming earnings report, particularly regarding the separation of its freight business, which is seen as an attractive risk-reward opportunity.
See More
Agilent Technologies Set to Release FY Earnings Results
- Earnings Announcement: Agilent Technologies is set to announce its FY earnings results on May 27th after market close, with consensus EPS estimate at $5.97 and revenue estimate at $7.39 billion, indicating strong financial expectations from the market.
- Performance Beat Record: Over the past two years, Agilent has beaten EPS estimates 88% of the time and revenue estimates 75% of the time, reflecting its sustained competitiveness and profitability in the market.
- Revision Trends: In the last three months, EPS estimates have seen 14 upward revisions and 2 downward revisions, while revenue estimates have experienced 15 upward revisions with no downward adjustments, showcasing analysts' optimistic outlook on the company's future performance.
- Strategic Acquisition: Agilent announced the acquisition of Biocare Medical for $950 million, aimed at expanding its pathology portfolio, which not only strengthens the company's market position but also has the potential to drive future revenue growth.
See More
Stock Market Shows Strength Ahead of Holiday Weekend
- Market Recovery: The S&P 500 index reached a record high above 7,500 in May after recovering from March lows, indicating strong market recovery, although it remains just below that record, reflecting optimistic investor sentiment.
- Declining Cash Holdings: A Bank of America Securities survey shows professional investors' cash levels dropped from 4.3% to 3.9%, nearing the 4.0% sell signal, indicating that investors are chasing the market rally but may soon face capital shortages.
- Increased Inflation Pressure: The upcoming personal consumption expenditures price index is expected to show core PCE rising to 3.4% year-over-year in April, up from 3.2% in March, potentially increasing pressure on the Federal Reserve to raise interest rates, which could affect market sentiment.
- Economic Data Impact: Next week will see several economic data releases and earnings reports from key tech companies that could significantly impact the markets, particularly consumer commentary from Costco and Dollar Tree, which may trigger market volatility.
See More
Agilent Technologies Declares Quarterly Dividend of $0.255
- Quarterly Dividend Announcement: Agilent Technologies has declared a quarterly dividend of $0.255 per share, consistent with previous announcements, reflecting the company's stable cash flow and profitability, which is likely to attract more income-focused investors.
- Dividend Yield: The forward yield of this dividend stands at 0.9%, which, while relatively low, still offers a return in the current market environment, potentially increasing investor interest in the company's stock.
- Consistent Dividend Payments: Agilent has now announced a dividend of $0.255 for three consecutive quarters, indicating confidence in future cash flows and potentially enhancing market perceptions of its financial health.
- Shareholder Record Date: The dividend will be payable on July 22 for shareholders of record on June 30, with the ex-dividend date also set for June 30, ensuring timely returns for shareholders and further solidifying trust between the company and its investors.
See More
